Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
72,686,329
-
Share change
-
-1,047,957
-
Total reported value
-
$1,479,214,886
-
Put/Call ratio
-
243%
-
Price per share
-
$20.35
-
Number of holders
-
178
-
Value change
-
-$18,971,939
-
Number of buys
-
111
-
Number of sells
-
69
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q2 2025
As of 30 Jun 2025,
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) was held by
178 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
72,686,329 shares.
The largest 10 holders included
Kynam Capital Management, LP, BlackRock, Inc., FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, Commodore Capital LP, Bellevue Group AG, Point72 Asset Management, L.P., and STATE STREET CORP.
This page lists
178
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.